Skip to main
IMRX

Immuneering Corp (IMRX) Stock Forecast & Price Target

Immuneering Corp (IMRX) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

The key points highlighting the positive outlook for Immuneering's stock include the demonstrated significant improvements in overall survival (OS) and progression-free survival (PFS) rates compared to current standard-of-care (SoC) treatments, suggesting enhanced efficacy of the company's drug candidates. Additionally, the safety profile of the therapy shows considerable improvement, with favorable tolerability of the drug atebimetinib and a modified regimen leading to better patient outcomes. Furthermore, the advancement of the lead asset, IMM-1-104, along with an extended operational runway through 2029, positions Immuneering to successfully execute its planned Phase III trials, potentially unlocking greater value.

Bears say

The financial outlook for Immuneering Corp faces significant downward pressure primarily due to substantial regulatory risks associated with the approval of its products. Should the company's lead candidate, IMM-1-104, fail to demonstrate distinct benefits in efficacy or tolerability compared to existing profiles, it could lead to revisions in financial estimates and overall valuation. Additionally, the potential need for further capital raises, possibly through equity financing, could dilute existing shareholder value, compounding the company's financial challenges before achieving profitability.

Immuneering Corp (IMRX) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immuneering Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immuneering Corp (IMRX) Forecast

Analysts have given Immuneering Corp (IMRX) a Buy based on their latest research and market trends.

According to 6 analysts, Immuneering Corp (IMRX) has a Buy consensus rating as of Mar 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immuneering Corp (IMRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.